Drug Profile
Idelalisib - Gilead Sciences
Alternative Names: CAL-101; GS-1101; IDELA; ZydeligLatest Information Update: 10 Nov 2022
Price :
$50
*
At a glance
- Originator Calistoga Pharmaceuticals
- Developer Augusta University; Calistoga Pharmaceuticals; Celgene Corporation; Gilead Sciences; Merck Sharp & Dohme; National Cancer Institute (USA)
- Class Antineoplastics; Purines; Quinazolinones; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Follicular lymphoma
- Phase III Non-Hodgkin's lymphoma
- Phase II Hodgkin's disease; Mantle-cell lymphoma; Waldenstrom's macroglobulinaemia
- Phase I/II Non-small cell lung cancer
- No development reported Diffuse large B cell lymphoma; Myelofibrosis; Pancreatic cancer
- Discontinued Allergic rhinitis; Solid tumours
Most Recent Events
- 27 Sep 2022 Gilead Sciences terminates a phase III trial in Follicular lymphoma (Second-line therapy or greater) in USA, Australia, Canada, Czech Republic, France, Israel, Italy, Poland, Romania, Spain, United Kingdom due to enrollment challenges faced by the company (PO) (NCT02536300)
- 14 Jan 2022 Launched for Chronic lymphocytic leukaemia (Combination therapy, First-line therapy) in United Kingdom (PO) as of January 2022 as of January 2022
- 14 Jan 2022 Launched for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in New Zealand, United Kingdom, Australia (PO) as of January 2022